Compass Therapeutics (CMPX) Return on Capital Employed (2023 - 2025)
Historic Return on Capital Employed for Compass Therapeutics (CMPX) over the last 3 years, with Q3 2025 value amounting to 0.44%.
- Compass Therapeutics' Return on Capital Employed fell 700.0% to 0.44% in Q3 2025 from the same period last year, while for Sep 2025 it was 0.44%, marking a year-over-year decrease of 700.0%. This contributed to the annual value of 0.41% for FY2024, which is N/A changed from last year.
- Per Compass Therapeutics' latest filing, its Return on Capital Employed stood at 0.44% for Q3 2025, which was down 700.0% from 0.62% recorded in Q2 2025.
- In the past 5 years, Compass Therapeutics' Return on Capital Employed registered a high of 0.32% during Q4 2023, and its lowest value of 0.62% during Q2 2025.
- In the last 3 years, Compass Therapeutics' Return on Capital Employed had a median value of 0.4% in 2024 and averaged 0.42%.
- Over the last 5 years, Compass Therapeutics' Return on Capital Employed had its largest YoY gain of -700bps in 2025, and its largest YoY loss of -2500bps in 2025.
- Compass Therapeutics' Return on Capital Employed (Quarter) stood at 0.32% in 2023, then decreased by -29bps to 0.42% in 2024, then dropped by -6bps to 0.44% in 2025.
- Its Return on Capital Employed stands at 0.44% for Q3 2025, versus 0.62% for Q2 2025 and 0.51% for Q1 2025.